Manuel Modiano MD

Oncology•Tucson, AZ

Breast Cancer, Gastrointestinal Cancer, Thoracic Cancer

Arizona Blood and Cancer Specialists. Medical Director, ACRC/Arizona Clinical Research Center. Tucson, AZ

Join to View Full Profile

3945 E Paradise Falls DrSte 105Tucson, AZ 85712
Phone+1 520-689-7030
Fax+1 520-395-9796

Education & Training

University of Arizona College of Medicine-TucsonFellowship, Hematology and Medical Oncology, 1987 - 1989
Aurora Health CareResidency, Internal Medicine, 1984 - 1987
Universidad Nacional Autonoma de MexicoClass of 1981

Certifications & Licensure

AZ State Medical License 1987 - 2025
WI State Medical License 1985 - 2025

Awards, Honors, & Recognition

Past President The Arizona Clinical Oncology Society
Certificate of Merit United States Surgeon General, 1991
Outstanding Fellow University of Arizona Cancer Center, 1988
Chief Resident Mount Sinai Medical Center, 1986
Outstanding Senior Resident Mount Sinai Medical Center, 1985-1986
Outstanding Medical Resident Mount Sinai Hospital, 1985
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Join now to see all

Clinical Trials

E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma Start of enrollment: 2011 Jul 19
Completed
Phase 1, Phase 2
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant Start of enrollment: 2011 Apr 20
Completed
Phase 3
E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2011 Sep 19
Completed
Phase 1, Phase 2
E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer Start of enrollment: 2011 Nov 01
Terminated
Phase 1, Phase 2
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors Start of enrollment: 2014 Jan 01
Completed
Phase 1
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread Start of enrollment: 2014 Jun 10
Completed
Phase 2
Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma Start of enrollment: 2014 Jun 01
Completed
Phase 1, Phase 2
A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer Start of enrollment: 2015 Jul 07
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

8 citations
Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma.
Darren Pan, Jonathan L Kaufman, Myo Htut, Manish Agrawal, Amitabha Mazumder
Cancer Medicine. 2022-01-01
14 citations
PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in ope...
Daniel P. Petrylak, Nicholas J. Vogelzang, Kamal Chatta, Mark D. Fleming, David Smith
The Prostate. 2020-01-01
33 citations
Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer
Lecia V. Sequist, Jhanelle E. Gray, Wael A. Harb, Ariel Lopez-Chavez, Robert C. Doebele
The Oncologist. 2019-08-01

Research History

Principal Investigator1989 - 2015

Professional Memberships

Other Languages

French, Spanish